Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Catabasis Pharmaceuticals (NASDAQ:CATB) announced that CEO Jill C. Milne, Ph.D., will present at the virtual Wedbush PacGrow Healthcare Conference on August 10, 2021, at 8:35 AM ET. The session titled “HAE There - Development Landscape in Hereditary Angioedema” will cover the treatment landscape for HAE, focusing on Catabasis's lead program, QLS-215, which is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development. A webcast of the session will be available for 30 days at the company’s website.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10^th, 2021 at 8:35am ET. The session entitled “HAE There- Development Landscape in Hereditary Angioedema (HAE)” will include an overview of the HAE treatment landscape, information about Catabasis’s lead program QLS-215, and a Q&A session.

A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740, and will also be available in the investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005076/en/

FAQ

What is the date and time of Catabasis Pharmaceuticals' presentation at the Wedbush PacGrow Healthcare Conference?

The presentation is scheduled for August 10, 2021, at 8:35 AM ET.

What is the focus of the upcoming presentation by Catabasis Pharmaceuticals?

The presentation will discuss the development landscape in Hereditary Angioedema (HAE) and highlight the lead program QLS-215.

Where can I watch the Catabasis Pharmaceuticals presentation?

The presentation will be webcasted, and you can watch it on the company’s website or directly at the provided webcast link.

What is QLS-215 and its significance in the presentation?

QLS-215 is Catabasis's lead program, a monoclonal antibody inhibitor of plasma kallikrein, currently in preclinical development for treating hereditary angioedema.